721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Authors :: A. Grauer
Domenica Lorusso
D.D. Nguyen
Nicoletta Colombo
Ana Oaknin
Gini F. Fleming
Rachel N. Grisham
T Van Gorp
H.I. Pashova
Source :: Annals of Oncology. 32:S725
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: business.industry
Phases of clinical research
Hematology
medicine.disease
Glucocorticoid receptor
Oncology
Cancer research
Medicine
In patient
Progression-free survival
Open label
business
Ovarian cancer
Nab-paclitaxel
Platinum resistant

Full Text Access

Tools